Predicting diabetes risk among HIV-positive and HIV-negative women

Karla I. Galaviz, Michael Schneider, Phyllis C. Tien, C. Christina Mehta, Ighovwerha Ofotokun, Jonathan Colasanti, Vincent C. Marconi, Kartika Palar, Gina Wingood, Adaora A. Adimora, Maria Alcaide, Mardge H. Cohen, Deborah Gustafson, Roksana Karim, Deborah Konkle-Parker, Daniel Merenstein, Anjali Sharma, Mohammed K. Ali

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: To assess the performance of an adapted American Diabetes Association (ADA) risk score and the concise Finnish Diabetes Risk Score (FINRISC) for predicting type 2 diabetes development in women with and at risk of HIV infection. DESIGN: Longitudinal analysis of the Women's Interagency HIV Study. METHODS: The women's Interagency HIV Study is an ongoing prospective cohort study of women with and at risk for HIV infection. Women without prevalent diabetes and 3-year data on fasting blood glucose, hemoglobin A1c, self-reported diabetes medication use, and self-reported diabetes were included. ADA and FINRISC scores were computed at baseline and their ability to predict diabetes development within 3 years was assessed [sensitivity, specificity and area under the receiver operating characteristics (AUROC) curve]. RESULTS: A total of 1111 HIV-positive (median age 41, 60% African American) and 454 HIV-negative women (median age 38, 63% African-American) were included. ADA sensitivity did not differ between HIV-positive (77%) and HIV-negative women (81%), while specificity was better in HIV-negative women (42 vs. 49%, P = 0.006). Overall ADA discrimination was suboptimal in both HIV-positive [AUROC = 0.64 (95% CI: 0.58, 0.70)] and HIV-negative women [AUROC = 0.67 (95% CI: 0.57, 0.77)]. FINRISC sensitivity and specificity did not differ between HIV-positive (72 and 49%, respectively) and HIV-negative women (86 and 52%, respectively). Overall FINRISC discrimination was suboptimal in HIV-positive [AUROC = 0.68 (95% CI: 0.62, 0.75)] and HIV-negative women [AUROC = 0.78 (95% CI: 0.66, 0.90)]. CONCLUSION: Model performance was suboptimal in women with and at risk of HIV, while greater misclassification was generally observed among HIV-positive women. HIV-specific risk factors known to contribute to diabetes risk should be explored in these models.

Original languageEnglish (US)
Pages (from-to)2767-2775
Number of pages9
JournalAIDS (London, England)
Volume32
Issue number18
DOIs
StatePublished - Nov 28 2018

Fingerprint

HIV
ROC Curve
African Americans
HIV Infections
Sensitivity and Specificity
Aptitude
Type 2 Diabetes Mellitus
Blood Glucose
Fasting
Hemoglobins
Cohort Studies
Prospective Studies

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Cite this

Galaviz, K. I., Schneider, M., Tien, P. C., Mehta, C. C., Ofotokun, I., Colasanti, J., ... Ali, M. K. (2018). Predicting diabetes risk among HIV-positive and HIV-negative women. AIDS (London, England), 32(18), 2767-2775. https://doi.org/10.1097/QAD.0000000000002017

Predicting diabetes risk among HIV-positive and HIV-negative women. / Galaviz, Karla I.; Schneider, Michael; Tien, Phyllis C.; Mehta, C. Christina; Ofotokun, Ighovwerha; Colasanti, Jonathan; Marconi, Vincent C.; Palar, Kartika; Wingood, Gina; Adimora, Adaora A.; Alcaide, Maria; Cohen, Mardge H.; Gustafson, Deborah; Karim, Roksana; Konkle-Parker, Deborah; Merenstein, Daniel; Sharma, Anjali; Ali, Mohammed K.

In: AIDS (London, England), Vol. 32, No. 18, 28.11.2018, p. 2767-2775.

Research output: Contribution to journalArticle

Galaviz, KI, Schneider, M, Tien, PC, Mehta, CC, Ofotokun, I, Colasanti, J, Marconi, VC, Palar, K, Wingood, G, Adimora, AA, Alcaide, M, Cohen, MH, Gustafson, D, Karim, R, Konkle-Parker, D, Merenstein, D, Sharma, A & Ali, MK 2018, 'Predicting diabetes risk among HIV-positive and HIV-negative women', AIDS (London, England), vol. 32, no. 18, pp. 2767-2775. https://doi.org/10.1097/QAD.0000000000002017
Galaviz, Karla I. ; Schneider, Michael ; Tien, Phyllis C. ; Mehta, C. Christina ; Ofotokun, Ighovwerha ; Colasanti, Jonathan ; Marconi, Vincent C. ; Palar, Kartika ; Wingood, Gina ; Adimora, Adaora A. ; Alcaide, Maria ; Cohen, Mardge H. ; Gustafson, Deborah ; Karim, Roksana ; Konkle-Parker, Deborah ; Merenstein, Daniel ; Sharma, Anjali ; Ali, Mohammed K. / Predicting diabetes risk among HIV-positive and HIV-negative women. In: AIDS (London, England). 2018 ; Vol. 32, No. 18. pp. 2767-2775.
@article{717dbaf631da4f2ebeb90a8e8a18039a,
title = "Predicting diabetes risk among HIV-positive and HIV-negative women",
abstract = "OBJECTIVE: To assess the performance of an adapted American Diabetes Association (ADA) risk score and the concise Finnish Diabetes Risk Score (FINRISC) for predicting type 2 diabetes development in women with and at risk of HIV infection. DESIGN: Longitudinal analysis of the Women's Interagency HIV Study. METHODS: The women's Interagency HIV Study is an ongoing prospective cohort study of women with and at risk for HIV infection. Women without prevalent diabetes and 3-year data on fasting blood glucose, hemoglobin A1c, self-reported diabetes medication use, and self-reported diabetes were included. ADA and FINRISC scores were computed at baseline and their ability to predict diabetes development within 3 years was assessed [sensitivity, specificity and area under the receiver operating characteristics (AUROC) curve]. RESULTS: A total of 1111 HIV-positive (median age 41, 60{\%} African American) and 454 HIV-negative women (median age 38, 63{\%} African-American) were included. ADA sensitivity did not differ between HIV-positive (77{\%}) and HIV-negative women (81{\%}), while specificity was better in HIV-negative women (42 vs. 49{\%}, P = 0.006). Overall ADA discrimination was suboptimal in both HIV-positive [AUROC = 0.64 (95{\%} CI: 0.58, 0.70)] and HIV-negative women [AUROC = 0.67 (95{\%} CI: 0.57, 0.77)]. FINRISC sensitivity and specificity did not differ between HIV-positive (72 and 49{\%}, respectively) and HIV-negative women (86 and 52{\%}, respectively). Overall FINRISC discrimination was suboptimal in HIV-positive [AUROC = 0.68 (95{\%} CI: 0.62, 0.75)] and HIV-negative women [AUROC = 0.78 (95{\%} CI: 0.66, 0.90)]. CONCLUSION: Model performance was suboptimal in women with and at risk of HIV, while greater misclassification was generally observed among HIV-positive women. HIV-specific risk factors known to contribute to diabetes risk should be explored in these models.",
author = "Galaviz, {Karla I.} and Michael Schneider and Tien, {Phyllis C.} and Mehta, {C. Christina} and Ighovwerha Ofotokun and Jonathan Colasanti and Marconi, {Vincent C.} and Kartika Palar and Gina Wingood and Adimora, {Adaora A.} and Maria Alcaide and Cohen, {Mardge H.} and Deborah Gustafson and Roksana Karim and Deborah Konkle-Parker and Daniel Merenstein and Anjali Sharma and Ali, {Mohammed K.}",
year = "2018",
month = "11",
day = "28",
doi = "10.1097/QAD.0000000000002017",
language = "English (US)",
volume = "32",
pages = "2767--2775",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",
number = "18",

}

TY - JOUR

T1 - Predicting diabetes risk among HIV-positive and HIV-negative women

AU - Galaviz, Karla I.

AU - Schneider, Michael

AU - Tien, Phyllis C.

AU - Mehta, C. Christina

AU - Ofotokun, Ighovwerha

AU - Colasanti, Jonathan

AU - Marconi, Vincent C.

AU - Palar, Kartika

AU - Wingood, Gina

AU - Adimora, Adaora A.

AU - Alcaide, Maria

AU - Cohen, Mardge H.

AU - Gustafson, Deborah

AU - Karim, Roksana

AU - Konkle-Parker, Deborah

AU - Merenstein, Daniel

AU - Sharma, Anjali

AU - Ali, Mohammed K.

PY - 2018/11/28

Y1 - 2018/11/28

N2 - OBJECTIVE: To assess the performance of an adapted American Diabetes Association (ADA) risk score and the concise Finnish Diabetes Risk Score (FINRISC) for predicting type 2 diabetes development in women with and at risk of HIV infection. DESIGN: Longitudinal analysis of the Women's Interagency HIV Study. METHODS: The women's Interagency HIV Study is an ongoing prospective cohort study of women with and at risk for HIV infection. Women without prevalent diabetes and 3-year data on fasting blood glucose, hemoglobin A1c, self-reported diabetes medication use, and self-reported diabetes were included. ADA and FINRISC scores were computed at baseline and their ability to predict diabetes development within 3 years was assessed [sensitivity, specificity and area under the receiver operating characteristics (AUROC) curve]. RESULTS: A total of 1111 HIV-positive (median age 41, 60% African American) and 454 HIV-negative women (median age 38, 63% African-American) were included. ADA sensitivity did not differ between HIV-positive (77%) and HIV-negative women (81%), while specificity was better in HIV-negative women (42 vs. 49%, P = 0.006). Overall ADA discrimination was suboptimal in both HIV-positive [AUROC = 0.64 (95% CI: 0.58, 0.70)] and HIV-negative women [AUROC = 0.67 (95% CI: 0.57, 0.77)]. FINRISC sensitivity and specificity did not differ between HIV-positive (72 and 49%, respectively) and HIV-negative women (86 and 52%, respectively). Overall FINRISC discrimination was suboptimal in HIV-positive [AUROC = 0.68 (95% CI: 0.62, 0.75)] and HIV-negative women [AUROC = 0.78 (95% CI: 0.66, 0.90)]. CONCLUSION: Model performance was suboptimal in women with and at risk of HIV, while greater misclassification was generally observed among HIV-positive women. HIV-specific risk factors known to contribute to diabetes risk should be explored in these models.

AB - OBJECTIVE: To assess the performance of an adapted American Diabetes Association (ADA) risk score and the concise Finnish Diabetes Risk Score (FINRISC) for predicting type 2 diabetes development in women with and at risk of HIV infection. DESIGN: Longitudinal analysis of the Women's Interagency HIV Study. METHODS: The women's Interagency HIV Study is an ongoing prospective cohort study of women with and at risk for HIV infection. Women without prevalent diabetes and 3-year data on fasting blood glucose, hemoglobin A1c, self-reported diabetes medication use, and self-reported diabetes were included. ADA and FINRISC scores were computed at baseline and their ability to predict diabetes development within 3 years was assessed [sensitivity, specificity and area under the receiver operating characteristics (AUROC) curve]. RESULTS: A total of 1111 HIV-positive (median age 41, 60% African American) and 454 HIV-negative women (median age 38, 63% African-American) were included. ADA sensitivity did not differ between HIV-positive (77%) and HIV-negative women (81%), while specificity was better in HIV-negative women (42 vs. 49%, P = 0.006). Overall ADA discrimination was suboptimal in both HIV-positive [AUROC = 0.64 (95% CI: 0.58, 0.70)] and HIV-negative women [AUROC = 0.67 (95% CI: 0.57, 0.77)]. FINRISC sensitivity and specificity did not differ between HIV-positive (72 and 49%, respectively) and HIV-negative women (86 and 52%, respectively). Overall FINRISC discrimination was suboptimal in HIV-positive [AUROC = 0.68 (95% CI: 0.62, 0.75)] and HIV-negative women [AUROC = 0.78 (95% CI: 0.66, 0.90)]. CONCLUSION: Model performance was suboptimal in women with and at risk of HIV, while greater misclassification was generally observed among HIV-positive women. HIV-specific risk factors known to contribute to diabetes risk should be explored in these models.

UR - http://www.scopus.com/inward/record.url?scp=85056412087&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056412087&partnerID=8YFLogxK

U2 - 10.1097/QAD.0000000000002017

DO - 10.1097/QAD.0000000000002017

M3 - Article

VL - 32

SP - 2767

EP - 2775

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 18

ER -